99mTc-PSMA SPECT/CT as a predictor of response to 177Lu-PSMA therapy in patients with metastatic castration-resistant prostate cancer.
Recruiting
- Conditions
- C61Malignant neoplasm of prostate
- Registration Number
- DRKS00029615
- Lead Sponsor
- Vivantes - Netzwerk für Gesundheit GmbH, Institut für Nuklearmedizin
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 30
Inclusion Criteria
Confirmed mCRPC, progressive disease, good general condition, exhausted recommended therapeutic options, recommendation of an interdisciplinary tumor conference.
Exclusion Criteria
Contradiction to the inclusion criteria.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PSA level and tumor volume at 12 weeks (after 2 cycles of therapy).
- Secondary Outcome Measures
Name Time Method 177Lu-PSMA uptake in posttherapeutic 177Lu-PSMA SPECT/CT.